Oral Psoriasis Drug Landscape

As of 2026-11-14, BMS’s Sotyktu and J&J’s Icotyde had US psoriasis approvals; Takeda’s zasocitinib was under Priority Review as a regulatory challenger.

Alumis reiterated on 2026-11-12 that 54% achieved PASI 100 at Week 48 in ONWARD3 with envudeucitinib; this extension result is not a head-to-head comparison.

Takeda announced on 2026-09-14 that the FDA target action window for zasocitinib was Q1 2027; that decision could change competition among approved oral drugs.

Oral Psoriasis Drug Landscape

Oral systemic drugs for plaque psoriasis, covering TYK2, IL-23R, PDE4 and A3 receptor approaches. PASI results from different trials are not an efficacy league table.

Competitive landscape

AssetCompanyMechanism / routeStageIndicationTrial identifierDealLatest developmentSource
Sotyktu / deucravacitinibBristol Myers SquibbUSAllosteric TYK2 inhibitorOralUS approvedAdult plaque psoriasis——Approved TYK2 benchmarkpackageinserts.bms.com
Icotyde / icotrokinraJohnson & JohnsonUSIL-23 receptor antagonist peptideOralUS approvedModerate-to-severe plaque psoriasis, age 12+, at least 40 kg——FDA approval 2026-03-17; four trials, 2,500 participants; company release dated March 18fda.gov
zasocitinib / TAK-279TakedaJapanTYK2 inhibitorOralFDA Priority ReviewModerate-to-severe plaque psoriasisNCT06973291—Head-to-head LATITUDE Atlas versus deucravacitinib; FDA target Q1 2027takeda.comtakeda.com.cn
envudeucitinibAlumisUSTYK2 inhibitorOralPhase 3 results; filing plannedModerate-to-severe plaque psoriasis——Week 48 PASI 100: 54%; NDA planned Q4 2026investors.alumis.comalumis.com
Otezla / apremilastAmgenUSPDE4 inhibitorOralUS approvedPlaque psoriasis; label-specific age and weight requirements——Established oral comparator, distinct from TYK2dailymed.nlm.nih.gov
piclidenoson / CF101Can-FiteIsraelA3 adenosine receptor agonistOralPhase 3 on company pipelinePlaque psoriasisNCT06643260—Investigational mechanism; unreported outcomes are not assumedcanfite.com
JSONCSV

Taiwan and Asia

Japan’s Takeda anchors the Asian coverage, with global Phase 3 and a direct comparison against deucravacitinib. The landscape also compares oral PDE4 and IL-23 receptor approaches; injectable products and distribution rights are outside this development field.